Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry

Alzheimer's and Dementia

Volumn 12, Issue 1, 2016, Pages 55-59

  Pannee, Josef ^a   Gobom, Johan ^a   Shaw, Leslie M ^b   Korecka, Magdalena ^b   Chambers, Erin E ^c   Lame, Mary ^c   Jenkins, Rand ^d   Mylott, William ^d   Carrillo, Maria C ^e   Zegers, Ingrid ^f   Zetterberg, Henrik ^a,g   Blennow, Kaj ^a   Portelius, Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WATERS CORPORATION   (United States)

^d Pharmaceutical Product Development   (United States)

^e ALZHEIMER'S ASSOCIATION   (United States)

^f JOINT RESEARCH CENTRE   (Italy)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Amyloid beta; Cerebrospinal fluid; Interlaboratory study; Mass spectrometry

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

ARTICLE; CALIBRATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LABORATORY TEST; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; ROUND ROBIN TEST; TANDEM MASS SPECTROMETRY; ALZHEIMER DISEASE; CEREBROSPINAL FLUID; PROCEDURES; STANDARD; STANDARDS; VALIDATION STUDY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CALIBRATION; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84954025387     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2015.06.1890     Document Type: Article

References (13)

1. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
2. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, J. Hardy, and et al. Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
3. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, S. Bernardini, and et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395.e6
4. N. Mattsson, U. Andreasson, S. Persson, M.C. Carrillo, S. Collins, S. Chalbot, and et al. CSF biomarker variability in the Alzheimer's Association quality control program Alzheimers Dement 9 2013 251 261
5. M.C. Carrillo, K. Blennow, H. Soares, P. Lewczuk, N. Mattsson, P. Oberoi, and et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium Alzheimers Dement 9 2013 137 140
6. J.H. Kang, M. Korecka, J.B. Toledo, J.Q. Trojanowski, and L.M. Shaw Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-beta1-42 and tau proteins as Alzheimer disease biomarkers Clin Chem 59 2013 903 916
7. S.A. Agger, L.C. Marney, and A.N. Hoofnagle Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry Clin Chem 56 2010 1804 1813
8. V. Kumar, D.R. Barnidge, L.S. Chen, J.M. Twentyman, K.W. Cradic, S.K. Grebe, and et al. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry Clin Chem 56 2010 306 313
9. C.G. Arsene, A. Henrion, N. Diekmann, J. Manolopoulou, and M. Bidlingmaier Quantification of growth hormone in serum by isotope dilution mass spectrometry Anal Biochem 401 2010 228 235
10. M.E. Lame, E.E. Chambers, and M. Blatnik Quantitation of amyloid beta peptides Aβ(1-38), Aβ(1-40), and Aβ(1-42) in human cerebrospinal fluid by ultra-performance liquid chromatography-tandem mass spectrometry Anal Biochem 419 2011 133 139
11. J. Pannee, E. Portelius, M. Oppermann, A. Atkins, M. Hornshaw, I. Zegers, and et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Abeta38, Abeta40, and Abeta42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls J Alzheimers Dis 33 2013 1021 1032
12. M. Korecka, T. Waligorska, M. Figurski, J.B. Toledo, S.E. Arnold, M. Grossman, and et al. Qualification of a surrogate matrix-based absolute quantification method for amyloid-beta42 in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry J Alzheimers Dis 41 2014 441 451
13. F.T. Peters, and H.H. Maurer Systematic comparison of bias and precision data obtained with multiple-point and one-point calibration in six validated multianalyte assays for quantification of drugs in human plasma Anal Chem 79 2007 4967 4976